Prairiewood Capital’s Anavex Life Sciences AVXL Stock Holding History

Prairiewood Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,800	Closed	-$123K	–	76
2025 Q3	$123K	Hold	13,800	–	–	0.04%	74
2025 Q2	$127K	Hold	13,800	–	–	0.05%	73
2025 Q1	$118K	Sell	13,800 -7,000	-34%	-$66.1K	0.05%	69
2024 Q4	$223K	Buy	+20,800	New	+$160K	0.1%	70

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Prairiewood Capital's AVXL Position: Q4 2025 in Review

Prairiewood Capital sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 13,800 shares — an estimated $123K sold.

Prairiewood Capital first reported a position in AVXL in Q4 2024 and held it in 4 quarters. The position peaked at $223K in Q4 2024. 183 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

Prairiewood Capital reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
Prairiewood Capital sold 13,800 Anavex Life Sciences shares in Q4 2025, an estimated $123K.
Prairiewood Capital first reported a position in Anavex Life Sciences in Q4 2024 and held it in 4 quarters.
Prairiewood Capital's Anavex Life Sciences position peaked at $223K in Q4 2024.
183 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Prairiewood Capital's 13F filing for Q4 2025, filed 26 Jan 2026.